Physician profile
Douglas Lee
NPI 1851654172
$1,104.07
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.86 · 2021: $209 · 2022: $394 · 2023: $393 · 2024: $87.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $199.48 | 2022-2023 | Da Vinci Surgical System |
| Iba Proton Therapy, INC. | $134.00 | 2021 | |
| Sumitomo Pharma America, INC. | $97.42 | 2023-2024 | Orgovyx |
| Boston Scientific Corporation | $96.34 | 2022 | |
| Gt Medical Technologies, INC | $77.32 | 2022 | |
| Reflexion Medical, INC. | $75.00 | 2021 | |
| Genzyme Corporation | $66.91 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $61.09 | 2023 | Keytruda |
| Taiho Oncology, INC. | $59.09 | 2022-2023 | |
| Janssen Biotech, INC. | $45.75 | 2023 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $42.85 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.54 | 2024 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $18.96 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $18.85 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.32 | 2023 | Kisqali |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $16.84 | 2022 | |
| Morphosys, US INC. | $16.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.